## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant  $\boxtimes$ 

Filed by a Party other than the Registrant o

Check the appropriate box:

- o Preliminary Proxy Statement
- o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- o Definitive Proxy Statement
- Definitive Additional Materials
- o Soliciting Material Pursuant to §240.14a-12

## IOVANCE BIOTHERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (check the appropriate box);

☑ No fee required.


- o Fee computed on table below per Exchange Act Rules 14a(i)(1) and 0-11.
  - (1) Title of each class of securities to which transaction applies:
  - (2) Aggregate number of securities to which transaction applies:
  - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
  - (4) Proposed maximum aggregate value of transaction:
  - (5) Total fee paid:

o Fee paid previously with preliminary materials.

- o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  - (1) Amount Previously Paid:
  - (2) Form, Schedule or Registration Statement No.:
  - (3) Filing Party:

(4) Date Filed:

## \*\*\* Exercise Your *Right* to Vote \*\*\* Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on June 06, 2018



Job # Job # Envelope # Sequence # # of # Sequence #

How to Access the Proxy Materials Proxy Materials Available to VIEW or RECEIVE: I. Annual Report 2. Notice & Proxy Statement How to View Online: Have the information that is printed in the box marked by the arrow  $\rightarrow$  xxxx xxxx xxxx xxxx xxxx (located on the following page) and visit: www.proxyvote.com. How to Request and Receive a PAPER or E-MAIL Copy: If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request: BY INTERNET: www.proxyvote.com 2) BY TELEPHONE: 1-800-579-1639 3) BY E-MAIL\*: sendmaterial@proxyvote.com \* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow  $\rightarrow$  xxxx xxxx xxxx xxxx (located on the following page) in the subject line. Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before May 23, 2018 to facilitate timely delivery.

Before You Vote

## — How To Vote —

Please Choose One of the Following Voting Methods

**Vote In Person:** If you choose to vote these shares in person at the meeting, you must request a "*legal proxy*." To do so, please follow the instructions at *www.proxyvote.com* or request a paper copy of the materials, which will contain the appropriate instructions. Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance.

**Vote By Internet:** To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow  $\rightarrow$  [xxxx xxxx xxxx xxxx] available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a voting instruction form.

Internal Use

Only

Voting	j items

The Board of Directors recommends that you vote FOR the following:

1. Election of Directors

Nominees

01 Iain Dukes, D. Phil 02 Maria Fardis, Ph.D. 03 Nichael Weiser M.D. PhD 04 Ryan Maynard 06 Wayne P. Rothbaum

05 Merrill A. McPeak

- The Board of Directors recommends you vote FOR the following proposal(s):
- 2. To approve, by non-binding advisory vote, the compensation of our named executive officers.
- 3. To approve the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan.
- To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018.

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

→ 0000 0000 0000 0000

Broadridge Internal Use Only
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
Cusip
Job #
Envelope #
Sequence #
# of # Soquence #

B A

R

C O

D

Е